CDK (cyclin-dependent kinase) inhibitor

Abemaciclib - Palbociclib - Ribociclib      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

abemaciclib
MONARCH 3, 2017Abemaciclib +nsAInsAI 1st line HER-2 negative HR positive postmenopausal NCT02246621Low risk of bias conclusive
palbociclib
PEARL ongoing palbociclib + exemestanecapecitabine HER-2 negative HR positive nsNAI failure NCT02028507Risk of bias ongoing
PALOMA 3, 2015palbociclib + fulvestrantfulvestrant alone2nd line 2nd line HER-2 negative HR positive NCT01942135Low risk of bias conclusive
PALOMA-4 ongoing palbociclib + letrozoleletrozole alone Asian HER-2 negative HR positive postmenopausal NCT02297438Low risk of bias ongoing
PALOMA-2, 2016palbociclib + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal NCT01740427Low risk of bias conclusive
PALOMA 1/TRIO-18, 2015palbociclib + letrozoleletrozole alone 1st line HER-2 negative HR positive postmenopausal NCT00721409Exploratory suggesting
PENELOPE-B ongoing palbociclibplacebo HR positive NCT01864746Low risk of bias ongoing
ribociclib
MONALEESA-3 ongoing ribociclib (LEE011)+ fulvestrantfulvestrant alone postmenopausal NCT02422615Low risk of bias ongoing
MONALEESA-2, 2016ribociclib (LEE011) + letrozoleletrozole alonefirst line 1st line HER-2 negative HR positive postmenopausal NCT01958021Low risk of bias conclusive
MONALEESA-7 ongoing ribociclib (LEE011) + nsAI/TAM gosnsAI/TAM + gos HER-2 negative HR positive premenopausal NCT02278120Low risk of bias ongoing

lung cancer (metastatic)

abemaciclib
JUNIPER, 2018abemacicliberlotinib2nd lineNCT02152631Risk of bias -